ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 220K)  | Related Articles | Citation Tracking

Effectiveness of Amitriptyline in the Prophylactic Management of Childhood Headaches
Andrew D. Hershey, MD, PhD; Scott W. Powers, PhD; Anna-Liisa Bentti, RN, MSN, CPNP; Ton J. deGrauw, MD, PhD
  From the Divisions of Neurology, Children's Hospital Medical Center, Cincinnati, Ohio.(Drs Hershey and deGrauw and Ms. Bentti)   Psychology, Children's Hospital Medical Center, Cincinnati, Ohio.(Dr. Powers)
Address all correspondence to Dr. Andrew D. Hershey, Headache Center, Children's Hospital Medical Center, Division of Neurology, 3333 Burnet Avenue, Cincinnati, OH 45229-3039.
Copyright American Headache Society
KEYWORDS
childhood headaches • migraines • amitriptyline • prophylaxis • chronic daily headaches

ABSTRACT

Objective.—To study the effectiveness of a standardized dose of amitriptyline, 1 mg/kg, for childhood headaches.

Background.—Amitriptyline has been shown to be effective for the prophylaxis of migraine in adults. Studies in children, however, have been quite limited. In adults, the suggested effective dose range is 10 to 150 mg. In children, a standardized dosage is often not used, resulting in a dosage range in clinical practice that often varies from a very low dose to a dose equivalent to that used in adults.

Methods.—Children with more than three headaches per month were treated with amitriptyline, slowly increasing the dose to 1 mg/kg per day. The frequency, severity, and duration of their headaches were initially evaluated and subsequently measured at each follow-up evaluation. Two hundred seventy-nine children had headaches occurring frequently enough to indicate prophylactic treatment. Of these children, 192 (68.8%) were treated with amitriptyline. The average age at presentation was 12.0 (± 3.0) years. The ratio of boys to girls was 1:1.74. The average frequency of headaches was 17.1 (± 10.1) days per month. The average severity was 6.84 (± 1.67) on a 10-point pain scale. The average duration was 11.5 (± 15.0) hours. The most frequent diagnoses using International Headache Society criteria were migraine (60.6%), migraine with aura (7.9%), and tension-type headache (10.4%). Of these children, 146 have been seen for at least one follow-up examination, occurring on average 67.3 (± 32.3) days after beginning prophylactic treatment.

Results.—A total of 84.2% of the children reported an overall perception of being better, while 11.6% reported being the same. The frequency of headaches improved to 9.2 (± 10.0) days per month. The average severity was reduced to 5.1 (± 2.1), and the average duration was reduced to 6.3 (± 11.1) hours. If daily or continuous headaches were excluded, the improvements were more marked. Minimal side effects were reported from these children and their families. Long-term evaluation (156 to 415 days) showed continued sustained improvement.

Conclusions.—Amitriptyline is an effective prophylactic medication for children with frequent headaches. A standardized dosing regimen results in a significant number of children responding with minimal side effects. The children are able to tolerate this dosing scheme and demonstrate good adherence to a dosing schedule of once a day.


Accepted for publication January 12, 2000.

DIGITAL OBJECT IDENTIFIER (DOI)
10.1046/j.1526-4610.2000.00085.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Latest News & Information
HEAD Impact Factor

Sign Up Now
Sign Up Now
Latest News & Information
AHS Facebook

Sign-up for Content Alerts
Latest News & Information

Sign up for the Neurology NewsWire.

Neuro Newsletter

Get 6 free issues of breaking news and research delivered to your inbox each year!

Sign Up Now

Sign Up Now

Be the first to know about new research in your field

Sign up for FREE e-alerts from Wiley-Blackwell journals!

Sign Up Now